| scholarly article | Q13442814 |
| P2093 | author name string | Chuan-Fen Liu | |
| Mark Perkins | |||
| Matthew L Maciejewski | |||
| Virginia Wang | |||
| Chris L Bryson | |||
| P2860 | cites work | Performance of comorbidity, risk adjustment, and functional status measures in expenditure prediction for patients with diabetes | Q30485139 |
| Length of comorbidity lookback period affected regression model performance of administrative health data | Q31052492 | ||
| Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization | Q34011243 | ||
| Copayment Reductions Generate Greater Medication Adherence In Targeted Patients | Q34147461 | ||
| The performance of administrative and self-reported measures for risk adjustment of Veterans Affairs expenditures | Q34337408 | ||
| Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance | Q35106942 | ||
| Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins | Q35734332 | ||
| Does medication adherence following a copayment increase differ by disease burden? | Q36085521 | ||
| Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability | Q36412624 | ||
| Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures | Q36547005 | ||
| Prescription drug cost sharing: associations with medication and medical utilization and spending and health. | Q36869615 | ||
| Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization | Q37260160 | ||
| Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. | Q37365655 | ||
| Observational methods in comparative effectiveness research | Q37823941 | ||
| Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? | Q42668163 | ||
| Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. | Q51758304 | ||
| The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. | Q51897196 | ||
| A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). | Q51914182 | ||
| The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. | Q52138533 | ||
| Evaluating Medication Effects Outside of Clinical Trials: New-User Designs | Q52956338 | ||
| Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands | Q63865861 | ||
| P433 | issue | 4 | |
| P921 | main subject | bias | Q742736 |
| P304 | page(s) | 1468-1486 | |
| P577 | publication date | 2013-02-13 | |
| P1433 | published in | Health Services Research | Q5690687 |
| P1476 | title | Potential bias in medication adherence studies of prevalent users | |
| P478 | volume | 48 |
| Q64106458 | Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review |
| Q60047628 | Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain |
| Q60303731 | Medication adherence among patients with Type 2 diabetes: A mixed methods study |
| Q55272311 | Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years. |
| Q34726493 | Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States |
| Q35541348 | Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient |
Search more.